Establishment Labs Holdings has delivered a strong 122.7% return over the past year, yet its valuation checks lean expensive, with the stock flagged as overvalued on market multiples and scoring poorly on broader value tests.

• Over the last 1 year, Establishment Labs Holdings has returned 122.7%, which puts extra attention on whether the current share price already reflects much of the good news.
• Expectations for continued business expansion and cash generation can support a premium, but any setback in execution or profitability may weigh heavily on what investors are willing to pay.
• On Simply Wall St's broader valuation framework, Establishment Labs Holdings passes 0 of 6 checks, which suggests it is not a clear bargain based on the current value score.

The issue now is whether Establishment Labs Holdings' share price is simply catching up with its story or has moved ahead of what its fundamentals can justify.

Establishment Labs Holdings delivered 122.7% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Has Establishment Labs Holdings Run Too Far on Sales?

The P/S ratio is a useful way to look at Establishment Labs Holdings because the company is still working through losses, which makes earnings-based measures less helpful.

The stock currently trades on a P/S of 11.9x, above the Medical Equipment industry average of 2.8x and also above the broader peer group at 2.2x. Simply Wall St’s tailored fair P/S ratio for Establishment Labs Holdings is 6.0x, which reflects its specific growth profile, margins, size and risk factors.

With the actual P/S standing close to double that fair ratio, the market is assigning a sizeable premium to each dollar of revenue at Establishment Labs Holdings compared with what the framework suggests is warranted.

On this P/S measure, Establishment Labs Holdings appears overvalued relative to both its own fair multiple and sector benchmarks.

See what the numbers say about this price — find out in our valuation breakdown.

The Establishment Labs Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Establishment Labs Holdings pick up from this valuation puzzle by spelling out which future paths for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. They sit on the company's Community page as structured cases that treat fair value as a thesis about the business that can be revisited as new information comes through.

Community views on Establishment Labs Holdings sit far apart, with one side seeing meaningful upside and the other focused on valuation risk.

Bull case: 7% undervalued

"Motiva implants are rapidly becoming essential for high-volume practices, and patient-driven demand is so strong that patients are willing to pay out-of-pocket rather than accept free competitor replacements..."

Read the full Bull Case to see why Establishment Labs Holdings could be undervalued

Bear case: 10% overvalued

"Rising societal emphasis on body positivity may prove to be a long-term headwind by fundamentally reducing demand for elective cosmetic surgeries, even as Establishment Labs accelerates commercial efforts and launches new products..."

Read the full Bear Case to see why Establishment Labs Holdings could be overvalued

Do you think there's more to the story for Establishment Labs Holdings? Head over to our Community to see what others are saying!

The Bottom Line

For investors looking at Establishment Labs Holdings today, the key issue is that the market-multiple work points to an overvalued stock, with the current P/S sitting well above both sector norms and the tailored fair ratio. That premium only makes sense if the company executes strongly enough on growth and profitability to keep justifying a higher price for each dollar of revenue. The crux of the debate from here is whether Establishment Labs Holdings can deliver on those expectations without disappointing, or whether the valuation gradually drifts back toward more typical industry and peer multiples.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.